Celltrion (O68270.KS)

Overall impact
B (62)

Commentary

Celltrion is a strong overall performer. With a 'B' rating of 62.1 for overall impact (67th percentile compared to all companies), Celltrion ranks 102nd out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 98 others, and ahead of Evolus, Oyster Point Pharma, Aurobindo Pharma and 49 others. On top material causes for Celltrion's industry (Pharmaceuticals & Biotech), Celltrion performs well in Technology Innovation (95.3 score), Child and Maternal Health (90.7) and Disease Eradication (96.4) and performs poorly in Sustainable Use of Water (39.6 score), Reduced Green House Gas Emissions (24.1) and Disaster Readiness and Effective Aid (36.5).
Impact
Cause O68270.KS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2002
Employees
2,572
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
South Korea
Share classes
O68270.KS
Description
Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.
Material causes
Ethos considers the following causes material for Celltrion, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.